First clinical studies with orlistat: a short review

Area of Science:

• Pharmacology
• Endocrinology
• Gastroenterology

Background:

• Obesity is a significant health concern.
• Lipase inhibition offers a potential therapeutic strategy by reducing dietary fat absorption.
• Orlistat is a known lipase inhibitor.

Purpose of the Study:

• To evaluate the efficacy of Orlistat in promoting weight loss in moderately obese individuals.
• To assess the impact of Orlistat on hormonal systems and gastrointestinal hormone responses.
• To determine the safety and tolerability of Orlistat.

Main Methods:

• A randomized, placebo-controlled study was conducted.
• Orlistat was administered at doses of 10 mg, 60 mg, and 120 mg three times daily.
• Fasting hormone levels and hormonal responses to a high-fat meal were measured.
• Weight loss and gastrointestinal side effects were recorded.

Main Results:

• Orlistat (50 mg TID) significantly increased weight loss compared to placebo in moderately obese subjects.
• Multiple doses (10, 60, 120 mg TID) confirmed significant weight loss versus placebo.
• No significant influence of Orlistat on fasting thyroid hormones, catecholamines, or IGF-I was observed.
• Gastrointestinal and pancreatic hormone responses post-meal were not significantly affected.
• Orlistat was generally well-tolerated, with an increased incidence of gastrointestinal side effects.

Conclusions:

• Lipase inhibition with Orlistat is an effective strategy for weight loss in obesity.
• Orlistat does not significantly alter key hormonal systems or postprandial hormone responses.
• Orlistat demonstrates a favorable safety profile, with gastrointestinal discomfort being the primary side effect.